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ABSTRACT
Objectives: To ascertain the extent of socioeconomic
and health condition inequalities in people with
diagnosed and undiagnosed diabetes and impaired
glucose regulation (IGR) in random samples of the
general population in England, as earlier diagnosis of
diabetes and treatment of people with IGR can reduce
adverse sequelae of diabetes. Various screening
instruments were compared to identify IGR, in addition
to undiagnosed diabetes.
Design: 5, annual cross-sectional health examination
surveys; data adjusted for complex survey design.
Setting: Random selection of private homes across
England, new sample annually 2009–2013.
Participants: 5, nationally representative random
samples of the general, free-living population: ≥1 adult
interviewed in 24 254 of 36 889 eligible addresses
selected. 18 399 adults had a valid glycated
haemoglobin (HbA1c) measurement and answered the
diabetes questions.
Main outcome measures: Diagnosed diabetes,
undiagnosed diabetes (HbA1c ≥48 mmol/mol), IGR
(HbA1c 42–47 mmol/mol).
Results: Overall, 11% of the population had IGR, 2%
undiagnosed and 6% diagnosed diabetes. Age-
standardised prevalence was highest among Asian
(19% (95% CI 16% to 23%), 3% (2% to 5%) and
12% (9% to 16%) respectively) and black participants
(17% (13% to 21%), 2% (1% to 4%) and 14% (9% to
20%) respectively). These were also higher among
people with lower income, less education, lower
occupational class and greater deprivation. Education
(OR 1.49 (95% CI 1.27 to 1.74) for no qualifications
vs degree or higher) and income (1.35 (1.12 to 1.62)
for lowest vs highest income quintile) remained
significantly associated with IGR or undiagnosed
diabetes on multivariate regression. The greatest odds
of IGR or undiagnosed diabetes were with increasing
age over 34 years (eg, OR 18.69 (11.53 to 30.28) aged
65–74 vs 16–24). Other significant associations were
ethnic group (Asian (3.91 (3.02 to 5.05)), African-
American (2.34 (1.62 to 3.38)) or ‘other’ (2.04 (1.07 to
3.88)) vs Caucasian); sex (OR 1.32(1.19 to 1.46) for
men vs women); body mass index (3.54 (2.52 to 4.96)
for morbidly obese vs not overweight); and waist
circumference (2.00 (1.67 to 2.38) for very high vs
low).
Conclusions: Social inequalities in hyperglycaemia
exist, additional to well-known demographic and
anthropometric risk factors for diabetes and IGR.
INTRODUCTION
Diabetes is a condition that can result in sig-
niﬁcant morbidity and mortality,1 exacer-
bated by the latent period of several years
during which diabetes is asymptomatic and
may therefore remain undiagnosed.2 During
this time, people are at risk of the complica-
tions of diabetes but being undiagnosed,
they do not receive treatment to reduce the
risks of cardiovascular or other diabetes-
Strengths and limitations of this study
▪ This study uses a nationally representative
sample of the free-living English population, with
18 399 participants, and non-response
weighting.
▪ The combination of (self-reported) diagnosis and
objectively measured glycated haemoglobin
allowed identification of those with undiagnosed
diabetes or impaired glucose regulation.
▪ Socioeconomic as well as health-related covari-
ates were used to show a wide range of associa-
tions with diabetes and impaired glucose
regulation.
▪ A weakness of the study is the single point of
data collection, making direction of effect some-
times hard to ascertain.
▪ Despite the large sample, some subsample
groups were small, and had correspondingly
wider CIs, for example, undiagnosed diabetics
(n=331), African-American (n=351), mixed
(n=182) and other ethnic groups (n=122).
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related diseases: at the time of diagnosis, up to 50% of
people with diabetes already have microvascular and
macrovascular complications.3 4 Early glycaemic control
can reduce complications,5 so targeted testing for dia-
betes is advocated by Diabetes UK6 and the American
Diabetes Association (ADA).7 In 2012, the National
Institute for Health and Care Excellence (NICE) pub-
lished guidelines recommending targeted screening to
identify undiagnosed diabetes in asymptomatic
populations.8
Recently, a further high-risk category has been recog-
nised: people with impaired glucose metabolism but
with blood glucose levels below the diabetic range,
referred to in this paper as having impaired glucose
regulation (IGR). Different deﬁnitions of IGR exist but
an International Expert Committee on the role of gly-
cated haemoglobin (HbA1c) in diagnosing diabetes sug-
gested that people with HbA1c of 42–47 mmol/mol
(6.0–6.5%)9 should be included in this group. NICE
adopted this recommendation in its 2012 guidance.8
Studies have shown an annual progression rate from
IGR to diabetes of 5–10%10 11 and that treatment can
prevent or delay progression to both diabetes12–15 and
its complications.16 17 For these reasons, NICE recom-
mends treating people with IGR, primarily with intensive
lifestyle interventions but with metformin and orlistat
where lifestyle changes fail or are inappropriate.8 These
guidelines have not yet been incorporated into the
Quality and Outcomes Framework (QOF) for general
practitioners (GPs).
Socioeconomic inequalities in health and risk factors
are well known,18 as is Hart’s19 inverse care law, that
those at highest need are least likely to receive health-
care. Rising obesity levels, which are socially patterned,20
have been paralleled by the increasing prevalence of
type 2 diabetes;21 22 information regarding trends in
diagnosed diabetes is available from QOF and the
National Diabetes Audit.23 24 These databases provide
information about patients, so may not accurately reﬂect
diabetes in the general population. In particular, they
do not tell us about IGR or undiagnosed diabetes, nor
do they provide information about social inequalities.
Nationally representative information about those with
undiagnosed diabetes and IGR is required to under-
stand, manage and reduce the potential impact of dia-
betes on population health. A recent report used Health
Survey for England (HSE) data to count and character-
ise people with non-diabetic hyperglycaemia (IGR) and
assess the relative utility of four risk scores.25 We
hypothesised that more deprived groups are likely to
have higher prevalence of IGR and undiagnosed dia-
betes, both for absolute prevalence and as a proportion
of all cases of diabetes. The objectives of this study were
to: determine the prevalence, and trends in prevalence,
of diagnosed and undiagnosed diabetes and IGR in
nationally representative data from the HSE; examine
socioeconomic and ethnic inequalities in IGR and
undiagnosed and diagnosed diabetes; and examine the
health status and biomarkers for cardiovascular disease
risk in people with these conditions. We also examined
the summary performance characteristics of various
current screening strategies.
METHODS
Participants
The HSE26 is an annual, cross-sectional, general popula-
tion survey of individuals living in private households in
England, randomly selected by address. Data collection
occurs throughout the year. The ﬁrst stage is a health
interview, including questions about diagnosed condi-
tions, self-rated health, and measured height and
weight. The second is a nurse visit, including further
physical measurements, recording prescribed medica-
tion and taking biological samples. All adults in selected
households are eligible for interview; all interviewed par-
ticipants are eligible for the nurse visit and biological
sampling. Most years, around 8000 adults have an inter-
view and around 6000 a nurse visit; all data collection
occurs in the participants’ own home.
For this analysis, survey data between 2009 and 2013
(during which time core questions and measurements
remained comparable) were included, to ensure subsam-
ples (particularly people with undiagnosed diabetes)
were as large as possible. Research ethics approval was
obtained from the relevant National Health Service
(NHS) National Research Ethics Service (NRES) com-
mittees prior to starting each year’s survey.
In total, 36 889 eligible households (occupied private
residences) were identiﬁed, of which at least one adult
was interviewed in 24 254 (66%) cooperating house-
holds. All 44 747 adults (aged 16+) in cooperating
households were eligible for interview, nurse visit and
blood sample: 38 761 (87%) were interviewed, 26 216
(59%) saw a nurse and 19 578 (44%) gave a blood
sample. Non-response was due to non-contacts, refusals
or inability to give informed consent (due to mental
capacity or language difﬁculties) at the individual inter-
view or nurse stage. Blood samples were not available
because of refusal, unsuccessful attempts to take blood
or medical reasons for ineligibility (including pregnancy,
anticoagulants or recent ﬁts).
The analytic sample comprised 18 399 adults who had
a valid HbA1c measurement and answered the diabetes
questions. The mean age was 51.3 years (SE 0.13); 45%
were male; 53% were in households headed by manager-
ial/professional or intermediate occupations. Four per
cent had missing occupation data, 15% missing income,
8% missing body mass index (BMI), 2% missing waist
circumference and <1% missing ethnicity. Missing data
for these were included as separate categories, to enable
inclusion of all participants. In total, 14 529 participants
were normoglycaemic, 2400 had IGR, 331 had undiag-
nosed diabetes and 1139 diagnosed diabetes. Restricting
the sample to those without diagnosed diabetes yielded
17 260 participants.
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Data
Diabetes and IGR definitions
Participants were grouped according to their HbA1c
result and their answers to questions on diagnosed dia-
betes. Those who reported that their doctor had diag-
nosed them with diabetes (except only when pregnant),
as well as those taking medication prescribed only for
diabetes, were categorised as ‘doctor-diagnosed dia-
betes’. Those not diagnosed with diabetes were cate-
gorised as ‘undiagnosed diabetes’ if HbA1c was
≥48 mmol/mol (>6.5%), IGR if 42–47 mmol/mol (6.0–
6.5%) and normoglycaemic if <42 mmol/mol (<6.0%).
Participant characteristics
Demographics and socioeconomic position
Age was grouped from 16 to 24 years to 75+ in 10 years
age groups. Ethnicity was self-assigned from a list of the
2001 or 2011 Census categories; categories used were
Caucasian, mixed, Asian, African-American and other.
Equivalised household income, adjusted for the number
of adults and children in the household, was divided into
quintiles within each survey year. Highest educational
qualiﬁcation was categorised as degree or equivalent; ‘A’
levels/NVQ3 or other higher qualiﬁcations below degree
level; other; and none.27 Occupational data were
grouped into the ﬁve-category National Statistics-Socio-
Economic Classiﬁcation (NS-SEC).28 Area deprivation
(the Index of Multiple Deprivation IMD 2007 for HSE
2009 and 2010, and IMD 2010 for HSE 2011–2013) was
divided into survey year-speciﬁc quintiles.29 All data were
self-reported except for area deprivation, which was
assigned from the participant’s postcode.
Anthropometry
BMI was calculated from height and weight measured by
the trained interviewers. Waist circumference was
measured by the trained nurses. BMI was ﬁrst categorised
as underweight (<18.5 kg/m2), desirable (18.5 to
<25 kg/m2), overweight (25 to <30 kg/m2), obese I (30
to <35 kg/m2), obese II (35 to <40 kg/m2) and morbidly
obese (≥40 kg/m2). A second categorisation used WHO
thresholds for Asian participants30 (<18, 18 to <23, 23 to
<27.5, ≥27.5 kg/m2), reﬂecting their greater risk of
diabetes at lower BMI levels. We subdivided the obese cat-
egories into 27.5 to <32.5, 32.5 to <37.5 and ≥37.5 kg/m2.
Third, black participants were also categorised using
those lower thresholds, as recommended by NICE in
2013.31 Similarly, waist circumference was ﬁrst categorised
as low (<94 cm in men, <80 cm in women), high (men
94–102 cm, women 80–88 cm) and very high (men
>102 cm, women >88 cm). Second, an ethnic group-
speciﬁc classiﬁcation was used, where the threshold for
low was <90 cm in Asian and black men but was
unchanged for other men and for all women. Third, sex-
independent international thresholds were used that are
more stringent for men: low <88 cm, high ≥88 cm in both
men and women. Finally, the NICE risk categorisation
using both BMI and waist circumference was also used.32
Other health measures
Self-rated general health was based on the answer to a
standard question about participants’ health in general.
Responses of very good and good were combined, as
were very bad and bad. Nurses measured blood pressure
three times after a 5 min rest, using an automated
device, the Omron HEM 307, with 1 min intervals
between each measurement. Categories of blood pres-
sure used information on medication prescribed for
blood pressure control as well as the mean of the
second and third measurements, limited to participants
who had not eaten, smoked, drunk alcohol or exercised
in the previous 30 min. In 2009 and 2010, a spot urine
was collected for laboratory measurement of albumin:
creatinine ratio (ACR). Microalbuminuria was deﬁned as
ACR 2.5–30 mg/mmol in men and 3.5–30 mg/mmol in
women and macroalbuminuria as ACR >30 mg/mmol in
either sex. In each year, blood samples were taken for
serum total and high-density lipoprotein (HDL) choles-
terol as well as the EDTA sample for HbA1c. Urine and
blood samples were posted to the Newcastle University
Hospitals laboratory, Newcastle-upon-Tyne, for assay. All
measurements used standard protocols which have been
reported elsewhere, along with laboratory methods and
quality assurance.33 34
Analyses and statistics
Weighting and complex survey design
Data were weighted for probability of address selection
(smaller regions were oversampled31), dwelling unit
selection (only one dwelling unit selected per address)
and household selection (only one household selected
per dwelling unit). In addition, the weights were cali-
brated for household non-response, and individual non-
response to interview, nurse visit or blood sample. The
HSE is designed to be representative of people living in
private households: non-response weighting is used to
correct for differential response compared with known
demographics from the census (age, sex, household
makeup, strategic health authority and social class of
household reference person), and differential response
to each stage of the survey. Since the analysis was limited
to those with blood samples, the ‘blood weights’ were
used.
The HSE uses a stratiﬁed clustered sample design, and
should not be treated as a simple random sample. The
strata variables supplied with each annual data set are
not identiﬁable and therefore identical strata cannot be
combined across years, so government ofﬁce region was
used as an alternative. Clusters/primary sampling units
were used as archived but recoded to avoid duplicated
identiﬁers across years (eg, cluster 1 in 2009 was a differ-
ent location to cluster 1 in 2010).
Analysis
Data were analysed using IBM SPSS V.20 (with complex
survey design module), with all signiﬁcance tests taking
account of the complex survey design (stratiﬁcation and
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clustering) and weighting. Differences between groups
are mentioned as being ‘signiﬁcant’ in this paper if
p<0.05. Prevalence of diagnosed and undiagnosed dia-
betes, and IGR are presented as crude proportions of
participants (weighted for non-response, and accounting
for complex survey design), and age-standardised and
sex-standardised (reweighted to give each occupation,
income, deprivation and ethnic group the same age and
sex proﬁle as the general population).
Logistic regression models were created, limited to parti-
cipants without diagnosed diabetes. The two outcomes
were (1) IGR or undiagnosed diabetes, and (2) undiag-
nosed diabetes. An outcome of IGR alone was not used as
any testing for IGR in clinical practice would also aim to
detect undiagnosed cases of diabetes. Explanatory vari-
ables considered were demographic (age group, sex,
ethnic group), socioeconomic factors and anthropometry.
The main six-category obesity variable and three-category
waist circumference were not collinear, with a correlation
of 0.162, so both were included in the initial model.
Missing data for the explanatory variables were included as
separate categories, to enable inclusion of all participants.
Income quintiles, educational qualiﬁcations, NS-SEC occu-
pational category and area deprivation quintiles were used
to assess socioeconomic inequalities. Of these, only
income quintiles and educational qualiﬁcations were
included in the ﬁnal regression models, as these were the
only variables which improved the ﬁt of the model with
the addition of each socioeconomic variable. Income and
educational qualiﬁcations had a correlation of 0.101.
The current health status and biomarkers of cardiovas-
cular risk of participants with IGR and undiagnosed or
diagnosed diabetes were also compared with those of
normoglycaemic participants, both as crude and
age-standardised and sex-standardised proportions.
Screening metrics
We also used our data to evaluate the effectiveness of
screening using different categories for BMI and/or waist
circumference, criteria for NHS Health Checks35 (inviting
people aged 40–75 or aged 25 and above from certain eth-
nicities) and the Diabetes UK/Leicester risk score tool
(but excluding family history of diabetes)36 37 as the cri-
teria for screening to identify IGR and undiagnosed dia-
betes. We calculated the sensitivity, speciﬁcity, positive
predictive value and negative predictive value for the
various criteria in this general population sample.
The STROBE checklist was used when writing this
manuscript. The raw data are available to download
from the UK Data Service.
RESULTS
Social inequalities in diabetes and IGR
There were marked socioeconomic gradients in preva-
lence of IGR and undiagnosed and diagnosed diabetes.
For area deprivation, inequalities in IGR (table 1) were
masked in the crude rates (see online supplementary
table S1) due to confounding by age. Inequalities in
IGR by income and education were attenuated by age/
sex standardisation but remained marked, with rates of
10% (95% CI 8% to 11%) in the lowest and 14% (12%
to 15%) in the highest income quintile and 10% (9% to
11%) for those with ‘A’ level/NVQ3 or higher educa-
tional qualiﬁcations and 14% (13% to 16%) for those
with no qualiﬁcations (table 1). The occupational classi-
ﬁcation showed higher IGR rates in participants in semi-
routine occupations or lower supervisory/technical
occupations than in other groups.
Prevalence of doctor-diagnosed diabetes across the
5 years was 6%, undiagnosed diabetes was 2%, and a
further 11% had IGR. In general, the characteristics of
people with diagnosed diabetes, undiagnosed diabetes
and IGR followed similar patterns: each increased with
age, overweight, lower socioeconomic position, and were
higher among minority ethnic groups than the white
population (after age standardisation). There were some
differences, for example, while both diagnosed and
undiagnosed diabetes were more common among men,
age-standardised prevalence of IGR was not different
between the sexes (table 1).
Predictors of IGR or undiagnosed diabetes
Among people without diagnosed diabetes, age was the
biggest risk factor, with those aged 75 and over having
almost 30 times higher odds of IGR/undiagnosed dia-
betes (table 2). The other important associations, which
each had an independent effect, were ethnicity and
both general and abdominal obesity. Unlike the preva-
lence ﬁgures, men had a 32% higher odds of IGR than
women.
Restricting the outcome to undiagnosed diabetes,
similar results were seen: although the sex difference,
effects of BMI and waist circumference and associations
with lower education were substantially greater, the odds
for black people was similar to that for white partici-
pants. However, income was no longer signiﬁcant.
Health status of those with IGR, undiagnosed or
diagnosed diabetes
Normoglycaemic people were generally the healthiest.
Those with IGR had higher rates than normoglycaemic
participants of hypertension, high total cholesterol, low
HDL cholesterol, high total:HDL ratio and albuminuria
(table 3). Many of these differences remained after
adjusting for the different age/sex proﬁle of the groups.
The proportion with untreated hypertension was highest
among those with undiagnosed diabetes; overall hyper-
tension rates were higher among those with diagnosed
or undiagnosed diabetes, and lower among normogly-
caemic and IGR participants. Those with undiagnosed
diabetes were also more likely to have poor levels of
HDL cholesterol, and a higher total:HDL cholesterol
ratio. Those with diagnosed diabetes were least likely to
have high total cholesterol.
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Table 1 Prevalence of IGR, undiagnosed and diagnosed diabetes; total diabetes and per cent undiagnosed; by sociodemographic indicators, with 95% CIs
N
Normoglycaemia
% (CI)
IGR
% (CI)
Undiagnosed
diabetes % (CI)*
Diagnosed
diabetes
% (CI)
All diabetes
% (CI)
Undiagnosed as
per cent of all
diabetes
All 18 399 82 (81 to 82) 11 (11 to 12) 1.6 (1.5 to 1.8) 6 (5 to 6) 7 (7 to 8) 23 (21–25)
Sex p=0.24 p<0.01 p<0.01 p<0.01 p=0.82
Men 8280 81 (80 to 82) 11 (10 to 12) 1.9 (1.6 to 2.2) 6 (6 to 7) 8 (8 to 9) 23 (20–26)
Women 10 119 82 (82 to 83) 11 (11 to 12) 1.4 (1.2 to 1.6) 5 (4 to 5) 6 (6 to 7) 23 (20–26)
Age group p<0.01 p<0.01 p<0.01 p<0.01 p=0.26
16–24 1267 97 (96 to 98) 2 (1 to 3) 0.1 (0.0 to 0.4) 1 (0 to 2) 1 (0 to 2) 12 (3–38)
25–34 2224 96 (95 to 97) 3 (2 to 3) 0.4 (0.2 to 0.8) 1 (1 to 2) 2 (1 to 2) 25 (13–43)
35–44 3254 91 (90 to 92) 6 (5 to 7) 1.1 (0.7 to 1.6) 2 (2 to 3) 3 (3 to 4) 32 (22–43)
45–54 3600 81 (80 to 83) 12 (11 to 13) 1.6 (1.1 to 2.1) 5 (4 to 6) 7 (6 to 8) 23 (17–30)
55–64 3354 71 (69 to 73) 18 (16 to 19) 2.8 (2.3 to 3.5) 8 (7 to 9) 11 (10 to 12) 25 (21–30)
65–74 2878 63 (61 to 65) 22 (20 to 23) 3.2 (2.6 to 4.0) 12 (11 to 14) 15 (14 to 17) 21 (17–25)
75+ 1822 52 (49 to 54) 29 (27 to 31) 3.9 (3.1 to 5.0) 16 (14 to 18) 20 (18 to 22) 20 (16–25)
HSE year (age-standardised and sex-standardised) p=0.17 p=0.01 p=0.12 p=0.03 p=0.04
2009 2290 83 (81 to 85) 11 (10 to 12) 1.5 (1.1 to 2.1) 5 (4 to 5) 6 (5 to 7) 26 (19–34)
2010 3856 82 (80 to 83) 12 (11 to 13) 1.1 (0.8 to 1.5) 5 (5 to 6) 6 (6 to 7) 16 (12–21)
2011 3902 80 (79 to 82) 12 (11 to 13) 2.1 (1.7 to 2.6) 6 (5 to 7) 8 (7 to 9) 26 (20–31)
2012 3886 83 (81 to 84) 10 (9 to 11) 1.9 (1.5 to 2.4) 5 (5 to 6) 7 (6 to 8) 27 (22–32)
2013 4465 82 (81 to 83) 11 (10 to 12) 1.5 (1.2 to 1.9) 6 (5 to 7) 7 (7 to 8) 20 (16–25)
Occupation (age-standardised and sex-standardised) p<0.01 p=0.02 p<0.01 p<0.01 p=0.16
Managerial/professional 6656 84 (83 to 85) 10 (9 to 11) 1.3 (1.0 to 1.6) 5 (4 to 5) 6 (5 to 6) 22 (18–27)
Intermediate 2700 84 (82 to 85) 10 (9 to 12) 1.2 (0.8 to 1.9) 5 (4 to 6) 6 (5 to 8) 19 (12–28)
Small employers/own account workers 1626 83 (80 to 85) 11 (9 to 14) 1.7 (1.2 to 2.5) 4 (3 to 6) 6 (5 to 8) 26 (17–37)
Lower supervisory/technical 1324 81 (78 to 83) 13 (11 to 15) 2.3 (1.5 to 3.4) 4 (3 to 6) 7 (5 to 8) 34 (24–46)
Semiroutine 5349 79 (77 to 80) 12 (11 to 13) 2.0 (1.6 to 2.5) 7 (6 to 8) 9 (8 to 10) 23 (19–28)
Equivalised household income (age-standardised and sex-standardised) p<0.01 p<0.01 p<0.01 p<0.01 p=0.70
Highest quintile 3446 86 (85 to 87) 10 (8 to 11) 1.0 (0.7 to 1.5) 3 (3 to 4) 4 (4 to 5) 22 (16–31)
Second highest 3514 85 (84 to 87) 9 (8 to 11) 1.4 (1.0 to 1.9) 4 (3 to 5) 5 (4 to 6) 27 (20–35)
Third 3215 83 (81 to 84) 11 (10 to 12) 1.3 (1.0 to 1.7) 5 (4 to 6) 6 (5 to 7) 20 (15–26)
Second lowest 2952 79 (77 to 81) 12 (11 to 13) 2.0 (1.5 to 2.6) 7 (6 to 8) 9 (8 to 11) 22 (17–28)
Lowest quintile 2394 77 (75 to 79) 14 (12 to 15) 2.2 (1.7 to 2.9) 7 (6 to 8) 9 (8 to 11) 0 (0–0)
Highest qualification (age-standardised and sex-standardised) p<0.01 p<0.01 p<0.01 p<0.01 p=0.07
Degree or above 4548 85 (84 to 86) 10 (9 to 11) 0.9 (0.6 to 1.2) 4 (3 to 5) 5 (4 to 6) 16 (11–23)
NVQ3/A level to below degree 4812 83 (81 to 84) 10 (9 to 11) 1.9 (1.5 to 2.3) 5 (4 to 6) 7 (6 to 8) 27 (22–33)
Other 5073 82 (81 to 83) 11 (10 to 12) 1.6 (1.3 to 2.1) 5 (5 to 6) 7 (6 to 8) 23 (18–29)
None 3949 76 (74 to 78) 14 (13 to 16) 2.2 (1.7 to 2.8) 8 (7 to 9) 10 (9 to 11) 22 (17–27)
Quintiles of area deprivation (age-standardised and sex-standardised) p<0.01 p<0.01 p<0.01 p<0.01 p=0.12
Least deprived 4093 86 (84 to 87) 10 (9 to 11) 1.0 (0.7 to 1.3) 4 (3 to 4) 5 (4 to 5) 20 (14 to 26)
Second lowest 4176 84 (82 to 85) 10 (9 to 11) 1.8 (1.4 to 2.2) 4 (4 to 5) 6 (5 to 7) 29 (23 to 35)
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Table 1 Continued
N
Normoglycaemia
% (CI)
IGR
% (CI)
Undiagnosed
diabetes % (CI)*
Diagnosed
diabetes
% (CI)
All diabetes
% (CI)
Undiagnosed as
per cent of all
diabetes
Middle 3850 82 (80 to 83) 11 (10 to 12) 1.6 (1.2 to 2.1) 5 (5 to 6) 7 (6 to 8) 23 (18–29)
Second highest 3354 79 (78 to 81) 12 (11 to 13) 1.8 (1.4 to 2.4) 7 (6 to 8) 9 (8 to 10) 20 (15–26)
Most deprived 2926 77 (75 to 78) 13 (11 to 14) 2.1 (1.7 to 2.7) 9 (8 to 10) 11 (10 to 12) 21 (16–26)
Ethnic specific BMI category† (age and sex-standardised) p<0.01 p<0.01 p<0.01 p<0.01 p=0.79
Not overweight 5622 89 (88 to 90) 8 (8 to 9) 0.6 (0.4 to 0.8) 2 (2 to 3) 3 (2 to 3) 19 (14–27)
Overweight 6633 85 (84 to 86) 10 (9 to 11) 1.1 (0.9 to 1.4) 4 (3 to 4) 5 (4 to 6) 22 (18–27)
Obese 1 3118 74 (72 to 76) 15 (14 to 17) 2.6 (2.1 to 3.2) 8 (7 to 9) 11 (10 to 12) 25 (19–31)
Obese 2 1006 67 (64 to 71) 16 (13 to 19) 3.9 (2.8 to 5.6) 13 (11 to 15) 17 (14 to 20) 24 (16–34)
Morbidly obese 429 55 (47 to 62) 20 (15 to 25) 6.0 (3.8 to 9.4) 20 (15 to 26) 26 (20 to 32) 24 (15–38)
Ethnic-specific waist‡ (age-standardised and sex-standardised) p<0.01 p<0.01 p<0.01 p<0.01 p=0.42
Low 5905 90 (89 to 90) 8 (7 to 9) 0.5 (0.3 to 0.7) 2 (2 to 2) 2 (2 to 3) 19 (12–27)
High 4451 85 (84 to 87) 10 (9 to 11) 1.0 (0.7 to 1.3) 4 (3 to 4) 5 (4 to 5) 23 (17–30)
Very high 7757 75 (74 to 77) 14 (13 to 15) 2.6 (2.3 to 3.1) 8 (7 to 9) 11 (10 to 12) 25 (21–29)
Ethnic group (age-standardised and sex-standardised) p<0.01 p<0.01 p<0.01 p<0.01 p=0.80
White 16 977 83 (82 to 84) 10 (10 to 11) 1.5 (1.3 to 1.7) 5 (5 to 5) 7 (6 to 7) 22 (20–25)
Mixed 182 81 (71 to 88) 10 (5 to 17) 3.5 (0.7 to 15.6) 6 (3 to 12) 10 (5 to 19)
Asian 748 65 (61 to 70) 19 (16 to 23) 3.3 (2.1 to 5.2) 12 (9 to 16) 16 (12–20)
Black 351 68 (61 to 74) 17 (13 to 21) 1.5 (0.6 to 3.6) 14 (9 to 20) 15 (11 to 21)
Other 122 72 (60 to 81) 13 (7 to 23) 3.0 (0.6 to 14.3) 12 (6 to 23) 15 (8 to 27)
All non-white 1403 68 (65 to 72) 16 (14 to 19) 3.1 (2.0 to 4.7) 12 (10 to 15) 15 (13 to 19) 21 (14–30)
*To show variation in the prevalence of undiagnosed diabetes, this is presented to one dp.
†Black and Asian participants: overweight: BMI 23 to <27.5 kg/m2; obese I: BMI 27.5 to <32.5 kg/m2; obese II: BMI 32.5 to <37.5 kg/m2; morbidly obese: BMI ≥37.5 kg/m2; other participants:
overweight: BMI 25 to <30 kg/m2; obese I: BMI 30 to <35 kg/m2; obese II: BMI 35 to <40 kg/m2; morbidly obese: BMI ≥40 kg/m2.
‡Black and Asian men: low <90 cm, high 90–102 cm, very high >102 cm; all other men: low <94 cm; high 94–102 cm; very high >102 cm; women (regardless of ethnicity): low <80 cm, high 80–
88 cm, very high >88 cm.
BMI, body mass index (kg/m2); HSE, Health Survey for England; IGR, impaired glucose regulation.
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Self-rated health showed a marked gradient, with the
age-standardised proportion reporting bad or very bad
health being low among normoglycaemic and IGR parti-
cipants and highest in those with diagnosed diabetes.
Screening instruments for IGR and/or undiagnosed
diabetes
Among those without diagnosed diabetes, a number of
possible screening criteria, using information that
should be readily available to individuals or their GPs,
were applied. Online supplementary table S2 shows the
screening characteristics in this general population
sample (excluding those with diagnosed diabetes),
along with the proportion of the population so identi-
ﬁed for screening. Despite the HSE data not including
family history of diabetes, the best measure examined
was based on the Diabetes UK/Leicester risk score,
ﬁnding 69% of people with IGR or undiagnosed dia-
betes with a speciﬁcity of 72% if using ‘moderate risk’
(score 16+).
DISCUSSION
Our study provides up-to-date information on prevalence
and trends in prevalence of diabetes, undiagnosed
Table 2 Logistic regression of factors associated with IGR or undiagnosed diabetes, or with undiagnosed diabetes
IGR or undiagnosed diabetes Undiagnosed diabetes
OR 95% CI p Value OR 95% CI p Value
Female 1 <0.001 1 <0.001
Male 1.32 1.19 to 1.46 <0.001 1.96 1.55 to 2.49 <0.001
16–24 1 <0.001 <0.001
25–34 1.47 0.87 to 2.49 0.154 3.12 0.64 to 15.08 0.158
35–44 3.32 2.02 to 5.47 <0.001 7.43 1.70 to 32.52 0.008
45–54 7.85 4.85 to 12.70 <0.001 11.22 2.70 to 46.56 0.001
55–64 14.26 8.91 to 22.84 <0.001 22.74 5.58 to 92.72 <0.001
65–74 18.69 11.53 to 30.28 <0.001 25.51 6.27 to 103.71 <0.001
75+ 29.48 18.15 to 47.88 <0.001 33.58 8.18 to 137.87 <0.001
White 1 <0.001 1 <0.001
Mixed 1.11 0.61 to 2.02 0.741 1.66 0.38 to 7.30 0.502
Asian 3.91 3.02 to 5.05 <0.001 4.51 2.81 to 7.25 <0.001
Black 2.34 1.62 to 3.38 <0.001 0.88 0.35 to 2.21 0.780
Other 2.04 1.07 to 3.88 0.030 1.26 0.26 to 6.21 0.777
Degree or higher 1 <0.001 1 0.004
A-level/NVQ3 to below degree 1.20 1.02 to 1.41 0.029 1.76 1.18 to 2.72 0.006
Other 1.24 1.06 to 1.44 0.006 1.53 0.98 to 2.38 0.060
No qualifications 1.49 1.27 to 1.74 <0.001 1.69 1.11 to 2.57 0.015
Highest income quintile‡ 1 0.002 1 0.160
Second highest 0.98 0.82 to 1.16 0.810 1.03 0.63 to 1.69 0.894
Middle 1.11 0.94 to 1.32 0.230 0.94 0.58 to 1.52 0.808
Second lowest 1.21 1.01 to 1.45 0.035 1.38 0.86 to 2.21 0.187
Lowest quintile 1.35 1.12 to 1.62 0.001 1.44 0.88 to 2.36 0.148
Missing 1.16 0.96 to 1.39 0.128 1.39 0.85 to 2.28 0.193
Ethnic-specific BMI categories* <0.001 <0.001
Not overweight 1 1
Overweight 1.02 0.87 to 1.20 0.834 1.18 0.73 to 1.91 0.502
Obese I 1.59 1.31 to 1.93 <0.001 2.56 1.58 to 4.14 <0.001
Obese II 2.05 1.58 to 2.65 <0.001 4.58 2.64 to 7.92 <0.001
Morbidly obese 3.54 2.52 to 4.96 <0.001 8.19 4.33 to 15.4 <0.001
Not measured 1.35 1.10 to 1.66 0.005 2.39 1.43 to 3.99 <0.001
Ethnic-specific waist circumference categories† <0.001 0.001
Low waist 1 1 0.00
High waist 1.41 1.19 to 1.67 <0.001 2.01 1.06 to 3.82 0.033
Very high waist 2.00 1.67 to 2.38 <0.001 4.41 2.35 to 8.27 <0.001
Not measured 2.11 1.47 to 3.03 <0.001 4.45 1.94 to 10.23 <0.001
*Black and Asian participants: overweight: BMI 23 to <27.5 kg/m2; obese I: BMI 27.5 to <32.5 kg/m2; obese II: BMI 32.5 to <37.5 kg/m2;
morbidly obese: BMI ≥37.5 kg/m2; other participants: overweight: BMI 25 to <30 kg/m2; obese I: BMI 30 to <35 kg/m2; obese II: BMI 35 to
<40 kg/m2; morbidly obese: BMI ≥40 kg/m2.
†Black and Asian men: low <90 cm, high 90–102 cm, very high >102 cm; all other men: low <94 cm; high 94–102 cm; very high >102 cm;
women (regardless of ethnicity): low <80 cm, high 80–88 cm, very high >88 cm.
‡Income was included for both models, although it was significantly associated only with IGR/undiagnosed diabetes.
Index of Multiple Deprivation was not included, as it did not improve the model significantly.
BMI, body mass index (kg/m2); IGR, impaired glucose regulation.
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Table 3 Prevalence of health conditions by glycaemia category
Unadjusted (crude) prevalence Age-standardised and sex-standardised prevalence
Normoglycaemia
(%)
IGR
(%)
Undiagnosed
diabetes (%)
Diagnosed
diabetes (%)
Normoglycaemia
(%)
IGR
(%)
Undiagnosed
diabetes (%)
Diagnosed
diabetes (%)
Blood pressure/hypertension
<130/80, no medication 57 33 20 18 55 47 32 33
<140/90 but not <130/80,
no medication
20 22 20 20 20 23 26 22
≥140/90, no medication 12 16 26 12 13 13 24 9
<130/80, on medication 3 9 13 18 4 5 6 14
<140/90 but not <130/80,
on medication
3 8 9 14 3 5 4 12
≥140/90, on medication 4 12 11 17 5 7 7 10
Total cholesterol
<4 mmol/L 11 9 8 34 11 11 5 26
4 to <5 mmol/L 31 24 27 38 30 23 22 39
≥5 mmol/L 58 67 65 28 59 65 73 35
HDL cholesterol
≥1 mmol/L 90 85 70 75 90 80 65 81
<1 mmol/L 10 15 30 25 10 20 35 19
Total:HDL cholesterol ratio
<5 81 72 54 80 81 65 45 81
≥5 19 28 46 20 19 35 55 19
<4 61 48 33 59 60 42 24 59
≥4 39 52 67 41 40 58 76 41
No albuminuria 94 89 83 76 93 90 90 78
Microalbuminuria* 6 10 16 22 6 9 9 20
Macroalbuminuria* 0 1 1 2 0 1 1 2
Self-reported general health
Very good/good 81 65 57 37 80 72 62 43
Fair 14 26 28 39 15 21 25 36
Very bad/bad 5 9 15 24 5 7 13 21
*Microalbuminuria: ACR 2.5–30 mg/mmol in men, 3.5–30 mg/mmol in women; macroalbuminuria: ACR >30 mg/mmol in either sex.
ACR, albumin:creatinine ratio; HDL, high-density lipoprotein; IGR, impaired glucose regulation.
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diabetes and IGR in the general population and social
inequalities in these. These survey data show the average
prevalence of diagnosed diabetes in adults aged 16+ in
England in 2009–2013 was 6%, the same as the preva-
lence reported by QOF over the 2012/2013 period
among those aged 17+.23 As expected, diabetes was
more prevalent with increasing age and obesity as well as
among males, people of black and Asian ethnicities and
those in lower socioeconomic positions. Around a
quarter of people with diabetes are still undiagnosed.
Consistent with previous work,38–42 HSE participants
with IGR have health characteristics between those with
normoglycaemia and with diabetes, supporting the idea
of a continuum of disease.43 44 We also showed that low
socioeconomic status, known to be associated with dia-
betes,45 46 is also associated with IGR; education was the
best marker. The prevalence of people with IGR is lower
than expected and appears to be static. There is a
graded association of cardiovascular characteristics
across the continuum of impaired glucose metabolism; a
diagnosis of diabetes appears to have beneﬁcial impacts
on risk factor modiﬁcation. A number of different
screening criteria can each identify the majority of those
with impaired glucose metabolism but support the use
of a validated risk assessment tool as the most sensitive
screening method.
The main strengths of this study are the analysis of
data from nationally representative random samples of
the free-living population, rather than limiting analysis
to those in the healthcare system with diagnoses or tests
of blood glucose levels. Non-response weighting, recom-
mended as the best approach to enhancing representa-
tiveness,47 was used, making these data as generalisable
as possible for England. Being a general health examin-
ation survey, the richness of data about each participant
enables wider examination than a diabetes-focused
study, hence the breadth of information on socio-
economic position and the range of variables that could
be examined. However, all surveys are limited in the
extent of the questionnaire; we had no information on
family history of diabetes, one component of the
Diabetes UK/Leicester risk score tool. A sizeable minor-
ity of data were missing for explanatory variables, espe-
cially income and BMI. These participants were retained
in the analysis, coded as a separate ‘missing’ category.
The nature of the study results in other limitations, par-
ticularly in how the categories of impaired glucose
metabolism were deﬁned. First, to be included in the
diagnosed diabetes group, participants needed to self-
report a diagnosis or be on diabetic medication. For this
reason, a proportion of diagnosed diabetics may have
been missed. The effect of this is likely to be small; fur-
thermore, if people do not report that they have dia-
betes and are not treating their condition, it may be
appropriate to consider them as undiagnosed diabetics.
Another problem is the use of a single HbA1c test to cat-
egorise participants. In practice, symptoms or a con-
ﬁrmatory test would often be used to diagnose diabetes
in people with an HbA1c of ≥48 mmol/mol.
Applications of such strict deﬁnitions might alter the
number of patients in each category but any such alter-
ation and its impact are likely to be small at a population
level. As discussed, impaired glucose metabolism is a
continuum, and although categories are deﬁned for
practical reasons, all those with raised HbA1c levels are
at risk and could beneﬁt from identiﬁcation and risk
reduction. Although the direction of association cannot
be determined in cross-sectional surveys, these are the
only ethical way to monitor trends in IGR and undiag-
nosed diabetes; cohort studies should always release
such results to their participants, thus new participants
are required for these analyses.
The HSE gives unique information about undiagnosed
populations and social inequalities in health, not avail-
able in routine data; until recently, prevalence estimates
of undiagnosed diabetes and IGR were based on
models.6 Unlike the recent Public Health England
report,25 we found marked socioeconomic inequalities
in IGR. They examined only deprivation quintiles but
failed to adjust for confounding by age; we also exam-
ined three individual-level markers of socioeconomic
position and found similar health inequalities, with edu-
cation and income remaining signiﬁcant in a multivari-
ate regression model with IGR or undiagnosed diabetes
as the outcome. We found the average prevalence of
undiagnosed diabetes in 2009–2013 was 1.6%.
Approximately 22% of people with diabetes remain
undiagnosed, a higher proportion than the Association
of Public Health Observatories (APHO) Diabetes
Prevalence Model estimates.6 This proportion has ﬂuctu-
ated over the 5 years, but the prevalence of both undiag-
nosed diabetes and IGR have not changed appreciably
over this time, possibly mirroring the stabilising preva-
lence of obesity in adults in England.20 It is too soon to
assess the impact of 2012 NICE guidance and the intro-
duction of targeted screening for earlier diagnosis.
The average IGR prevalence was 11%, with no discern-
ible trend over our 5 years of data. This contrasts starkly
with another recent study using HSE data that suggested
an increase in IGR prevalence from 11.6% in 2003 to
35.3% in 2011.48 This is explained by the differences
between deﬁnitions of IGR. We used an HbA1c range of
42–47 mmol/mol, as recommended by an international
expert panel, NICE and Diabetes UK,6 8 whereas
Mainous et al used a range of 39–47 mmol/mol (5.7–
6.4%) as recommended by ADA,7 ﬁnding similar 2011
prevalence in the UK as in the USA using the same def-
inition.49 Our own ﬁndings, using the same data set for
this paper, are that using a deﬁnition of 39–47 mmol/
mol, IGR was 31.2% (30.4% to 32.1%) 2009–2013, and
tended to decrease since 2010 (34%) to 28% in 2013.
Overall, the proportion with HbA1c 39 mmol/mol or
above was 38.4%, increasing from 2009 (37.7%) to 2011
(41.2%) before decreasing again to 35.9% in 2013.
The differences between the results for the different
thresholds suggest that there is an increasing prevalence
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of people with an HbA1c of 39–41 mmol/mol but not
with an HBA1c of 42–47 mmol/mol. There are two
potential explanations for this. First, there may be a lag
period and the impact of the increasing prevalence of
those with lower range IGR is yet to be felt. The second
explanation is that people with lower range IGR do not
necessarily develop increasingly deranged glucose
metabolism, meaning a change in prevalence of this
group would not necessarily be reﬂected in groups with
higher HbA1c levels. If this is the case, it would provide
signiﬁcant support for the use of an HbA1c of
42 mmol/mol as the lower threshold for IGR as per
current UK recommendations.
We showed a continued increase in the prevalence of
diabetes over the 5 years, consistent with information from
other databases.23 24 This is unsurprising in the context of
rising levels of obesity but provides concerning insight into
the potential impact of this serious and costly condition
on population health in the future. A large proportion of
people with diabetes are still undiagnosed, so do not
beneﬁt from the potential advantages that a diagnosis
carries. Modelling studies have suggested a beneﬁt in
using screening to detect early diabetes.50 51 In contrast,
recent data from the ADDITION trial52 does not show a
reduction in mortality with screening for diabetes. In
terms of biomarkers, our data support the assumption that
a diagnosis can be beneﬁcial,53 particularly for lipid and
blood pressure modiﬁcation: people who are diagnosed
will beneﬁt from QOF and guideline-driven risk factor
modiﬁcation, resulting in a stalling or reduction of cardio-
vascular risk factor progression despite advancing disease.
However, self-reported health was worst in this group.
There is a clear case for identifying IGR as cost-
effective interventions exist to prevent or delay dia-
betes6 8 54 55 for people in this category. Our lower
prevalence of IGR implies that interventions to manage
this population may be more feasible and less costly
than was anticipated based on an earlier study.38 IGR
and undiagnosed diabetes are more prevalent in more
deprived groups, even after adjusting for demographic
factors and obesity. Undiagnosed diabetes as a propor-
tion of all cases is also higher in these groups. It is
recognised that individual ‘agentic’ interventions may
widen inequalities, as disadvantaged groups are less
likely to participate.56 Thus, only if GPs manage to
target deprived groups successfully for detection and
support with lifestyle modiﬁcation, this programme
could reduce social inequalities in health. Similarly,
focusing screening and advice by occupational health
departments on employees in lower supervisory and
technical and semiroutine occupations could also
reduce health inequalities and employee morbidity.
Future health examination surveys are needed to
monitor continuing trends in changes in national
prevalence and social inequalities of IGR and undiag-
nosed diabetes, as clinical commissioning groups pilot
and roll out detection and intervention programmes.
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